Martingale Asset Management L P Crinetics Pharmaceuticals, Inc. Transaction History
Martingale Asset Management L P
- $3.87 Billion
- Q1 2025
A detailed history of Martingale Asset Management L P transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Martingale Asset Management L P holds 6,701 shares of CRNX stock, worth $221,669. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,701
Previous 22,484
70.2%
Holding current value
$221,669
Previous $1.15 Million
80.5%
% of portfolio
0.01%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding CRNX
# of Institutions
235Shares Held
87MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$308 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$228 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$206 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$206 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$169 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.78B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...